82 related articles for article (PubMed ID: 19220542)
21. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
Lee SS; Park YW; Park JJ; Kang YM; Nam EJ; Kim SI; Lee JH; Yoo WH; Lee SI
Scand J Rheumatol; 2009; 38(1):11-4. PubMed ID: 19191187
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
Poór G; Strand V;
Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
[TBL] [Abstract][Full Text] [Related]
23. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.
Van Roon EN; Jansen TL; Mourad L; Houtman PM; Bruyn GA; Griep EN; Wilffert B; Tobi H; Brouwers JR
Br J Clin Pharmacol; 2004 Aug; 58(2):201-8. PubMed ID: 15255803
[TBL] [Abstract][Full Text] [Related]
24. Leflunomide-associated infections in rheumatoid arthritis.
Jenks KA; Stamp LK; O'Donnell JL; Savage RL; Chapman PT
J Rheumatol; 2007 Nov; 34(11):2201-3. PubMed ID: 17937473
[TBL] [Abstract][Full Text] [Related]
25. Leflunomide.
Cohen SB; Iqbal I
Int J Clin Pract; 2003 Mar; 57(2):115-20. PubMed ID: 12661795
[TBL] [Abstract][Full Text] [Related]
26. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
Goldenberg MM
Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
[TBL] [Abstract][Full Text] [Related]
27. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
Ollendorf DA; Peterson AN; Doyle J; Huse DM
Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
[TBL] [Abstract][Full Text] [Related]
28. Maintenance of remission with leflunomide in Wegener's granulomatosis.
Metzler C; Fink C; Lamprecht P; Gross WL; Reinhold-Keller E
Rheumatology (Oxford); 2004 Mar; 43(3):315-20. PubMed ID: 14963200
[TBL] [Abstract][Full Text] [Related]
29. Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug.
Prescrire Int; 2001 Apr; 10(52):36-9. PubMed ID: 11718154
[TBL] [Abstract][Full Text] [Related]
30. Rheumatoid arthritis treatment with weekly leflunomide: an open-label study.
Jaimes-Hernández J; Robles-San Román M; Suárez-Otero R; Dávalos-Zugasti ME; Arroyo-Borrego S
J Rheumatol; 2004 Feb; 31(2):235-7. PubMed ID: 14760790
[TBL] [Abstract][Full Text] [Related]
31. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis.
Sawada T; Inokuma S; Sato T; Otsuka T; Saeki Y; Takeuchi T; Matsuda T; Takemura T; Sagawa A;
Rheumatology (Oxford); 2009 Sep; 48(9):1069-72. PubMed ID: 19321513
[TBL] [Abstract][Full Text] [Related]
32. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
Wang HY; Cui TG; Hou FF; Ni ZH; Chen XM; Lu FM; Xu FF; Yu XQ; Zhang FS; Zhao XZ; Zhao MH; Wang GB; Qian JQ; Cai GY; Zhu TY; Wang YH; Jiang ZP; Li YN; Mei CL; Zou WZ;
Lupus; 2008 Jul; 17(7):638-44. PubMed ID: 18625636
[TBL] [Abstract][Full Text] [Related]
33. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients.
Siva C; Eisen SA; Shepherd R; Cunningham F; Fang MA; Finch W; Salisbury D; Singh JA; Stern R; Zarabadi SA
Arthritis Rheum; 2003 Dec; 49(6):745-51. PubMed ID: 14673959
[TBL] [Abstract][Full Text] [Related]
34. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
35. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
36. The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis.
Saruhan-Direskeneli G; Inanc M; Fresko I; Akkoc N; Dalkilic E; Erken E; Karaaslan Y; Kinikli G; Oksel F; Pay S; Yucel E; Yentür SP; Duymaz-Tozkir J; Yilmaz V; Inanc N; Yazici H; Konice M; Direskeneli H
Rheumatology (Oxford); 2007 Dec; 46(12):1842-4. PubMed ID: 18032542
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.
Weinblatt ME; Kremer JM; Coblyn JS; Maier AL; Helfgott SM; Morrell M; Byrne VM; Kaymakcian MV; Strand V
Arthritis Rheum; 1999 Jul; 42(7):1322-8. PubMed ID: 10403258
[TBL] [Abstract][Full Text] [Related]
38. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Agarwal S; Zaman T; Handa R
Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
[TBL] [Abstract][Full Text] [Related]
39. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study.
de Souza AW; da Silva MD; Machado LS; Oliveira AC; Pinheiro FA; Sato EI
Scand J Rheumatol; 2012 May; 41(3):227-30. PubMed ID: 22400913
[TBL] [Abstract][Full Text] [Related]
40. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified?
Rajakulendran S; Gadsby K; Deighton C
Musculoskeletal Care; 2008 Dec; 6(4):233-45. PubMed ID: 18702106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
